Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Renée Bouwstra"'
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 8, Pp n/a-n/a (2022)
Abstract Background The CD47‐signal regulatory protein alpha (SIRPα) ‘don't eat me’ signalling axis is perhaps the most prominent innate immune checkpoint to date. However, from initial clinical trials, it is evident that monotherapy with CD47
Externí odkaz:
https://doaj.org/article/f615f76d908349ff965abe2f6a669b2e
Autor:
Tom van Meerten, Edwin Bremer, Gerwin Huls, Marcel Nijland, Christine zu Eulenburg, Emanuele Ammatuna, Rudolf S.N. Fehrmann, Ewa Cendrowicz, Hilde Kooistra, Janneke de Boer, Yuan He, Renée Bouwstra
GEO accession numbers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2511c125c1c9d6e61022fbe7f1b022ba
https://doi.org/10.1158/2326-6066.22542187.v1
https://doi.org/10.1158/2326-6066.22542187.v1
Autor:
Tom van Meerten, Edwin Bremer, Gerwin Huls, Marcel Nijland, Christine zu Eulenburg, Emanuele Ammatuna, Rudolf S.N. Fehrmann, Ewa Cendrowicz, Hilde Kooistra, Janneke de Boer, Yuan He, Renée Bouwstra
Supplemental Figure 1. (A) Kaplan Meijer curves for patients with high or low CD47 expression treated with CHOP or R-CHOP. (B) Kaplan Meijer curves for DLBCL patients treated with CHOP or R-CHOP Supplemental Figure 2. (A) non-GCB have significantly h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f5bb9a8464d8023ac81a14b48b02260
https://doi.org/10.1158/2326-6066.22542193
https://doi.org/10.1158/2326-6066.22542193
Autor:
Tom van Meerten, Edwin Bremer, Gerwin Huls, Marcel Nijland, Christine zu Eulenburg, Emanuele Ammatuna, Rudolf S.N. Fehrmann, Ewa Cendrowicz, Hilde Kooistra, Janneke de Boer, Yuan He, Renée Bouwstra
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0042f8a86b9433a6883503cb5df70935
https://doi.org/10.1158/2326-6066.22542190
https://doi.org/10.1158/2326-6066.22542190
Autor:
Tom van Meerten, Edwin Bremer, Gerwin Huls, Marcel Nijland, Christine zu Eulenburg, Emanuele Ammatuna, Rudolf S.N. Fehrmann, Ewa Cendrowicz, Hilde Kooistra, Janneke de Boer, Yuan He, Renée Bouwstra
Addition of rituximab (R) to “CHOP” (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients who receive R-CHOP still succumb to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1941d1c73da99aacdaa861944aa7dcde
https://doi.org/10.1158/2326-6066.c.6549826
https://doi.org/10.1158/2326-6066.c.6549826
Autor:
Bouwstra, Renée1 (AUTHOR) r.e.bouwstra@umcg.nl, van Meerten, Tom1 (AUTHOR), Bremer, Edwin1 (AUTHOR)
Publikováno v:
Clinical & Translational Medicine. Aug2022, Vol. 12 Issue 8, p1-25. 25p.